Patents Assigned to SmithKline Beecham Biologicals (s.a.)
  • Hybrid protein between CS from plasmodium and HBsAg
    Patent number: 5928902
    Abstract: A novel hybrid protein is provided which comprises a portion of the CS protein of P. falciparum and the surface antigen of Hepatitis B virus. The use of this protein for vaccination purposes is disclosed.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: July 27, 1999
    Assignee: SmithKline Beecham Biologicals (s.a.)
    Inventors: Michel De Wilde, Joseph Cohen
  • Vaccine
    Patent number: 5786189
    Abstract: The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: July 28, 1998
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Camille Locht, Yves Lobet
  • Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
    Patent number: 5776468
    Abstract: Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: July 7, 1998
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Pierre Hauser, Pierre Voet, Moncef Slaoui, Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Desmons
  • Vaccine composition containing adjuvants
    Patent number: 5750110
    Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and .gamma. IFN responses.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: May 12, 1998
    Assignee: SmithKline Beecham Biologicals, s.a
    Inventors: John Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala
  • HCMV/HSV fusion glycoproteins
    Patent number: 5739292
    Abstract: A fusion protein comprising a portion of a glycoprotein of HCMV fused to a portion of a glycoprotein of HSV is described.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: April 14, 1998
    Assignee: SmithKline Beecham Biologicals (s.a.)
    Inventor: Dirk Richard Gheysen